Relapsing-Remitting MS

Who is eligible to participate in the EVOLVE-MS-1 study?

To be eligible for this study, you must:

  • Be 18 to 65 years of age
  • Have been diagnosed with RRMS
  • Not have a diagnosis of primary progressive, secondary progressive, or progressive relapsing MS

Other eligibility criteria apply. All study-related visits, tests, and the study drug (ALKS 8700) will be provided at no cost to you. In addition, reimbursement for study-related expenses may be provided.

What are the risks and benefits related to the EVOLVE-MS-1 study?

While ALKS 8700 could be helpful in treating your RRMS, there is no guarantee that participating in this study will help your condition, and it is possible your RRMS could still progress. You may also experience side effects.

In previous studies of ALKS 8700, the most common side effect was flushing (redness, sensation of warmth, and/or itching of the skin). The study staff will provide you with a complete list of possible side effects related to the experimental drug and this study.

Because research studies can affect the health and safety of participants, you will be closely monitored during this study. Researchers for this study designed a protocol, which explains all of the study procedures in complete detail. An independent review board responsible for participant safety reviewed and approved this protocol and requires that it be followed exactly.

What if I have questions?

The EVOLVE-MS-1 study staff is always available to answer any questions or concerns you may have about the study or the experimental drug.

Epilepsy with Partial Seizures

If you have been diagnosed with Epilepsy with partial seizures and are currently taking up to three medications for its control, you may be eligible to participate in a research study evaluating an investigational medication to be added to your current therapy.


All study-related visits and tests are provided at no cost for the study duration. In addition, epilepsy medication prescribed by the study doctor will be provided to you for six months after you complete the study.


Reimbursement for travel and inconvenience is also provided.


What is the ASCENT Study?

The ASCENT Study is a clinical research study evaluating a medication for patients diagnosed with COPD who also have a history of heart disease, stroke or other risk factors.

The purpose of this study is to determine how the medication manages and controls COPD symptoms as well as how it affects patients’ cardiovascular safety.

You may Qualify if you:

• Are 40 years of age or older
• Are a current or former smoker
• Have been diagnosed with COPD, which includes chronic bronchitis and emphysema
• Have a history of heart disease, stroke, or
• Have other cardiovascular risk factors such as diabetes, high blood pressure, high cholesterol, obesity or kidney disease

By participating in the ASCENT Study, you will receive:

• Monitoring of your COPD by a physician during study visits
• Study-related care and study medication, including a rescue inhaler at no cost*

*You do not need insurance to participate.


From widespread burning to localized stabbing, everyone experiences fibromyalgia pain differently.

If you’re an adult living with fibromyalgia, or suspect you are, local doctors need your help with a research study testing an investigational medication designed specifically for your kind of pain. Qualified participants in this research study will be seen by a doctor and receive all study-related care, tests and medications at no cost. Compensation for time and travel may be available.

No one should have to live with the pain of fibromyalgia.

Call to learn more about this research study.

Migraine Study

You could be eligible for a research study that involves completing a survey online to collect information regarding your symptoms, medication use and impacts on your life.

Local doctors are looking for people who experience migraines and who may be taking a preventative medication to treat migraines.

To qualify for this study, you must:

  • Have recently started taking a preventative medication to treat migraines (or will be starting to take one)
  • Be between 18 and 65 years of age
  • Have a history of migraines for 1 year or more prior to the study
  • Have at least 4 days of migraines per month for 3 months prior to the study
  • Meet other study eligibility criteria


If you qualify, compensation will be provided for study participation.


To learn more, please contact:

Onsite Clinical Solutions, Lexington NC
Robert Austin